RB1 and mantle cell lymphoma: As expected, the loss of CDKN1C in erdafitinib-treated MCL cells restored the expression of RB and its phosphorylation (Fig. 5G) and upregulation in E2F1 target gene expression (Fig. 5H) with no change in levels of E2F1 (Fig. S6A).